Reason MNKD stock is down today is because analysts NOT diabetics making medical decisions
1. Diabetics will choose rapid acting insulin.
2. The competition slower acting insulin market is about $6 billion, about half of that is Humalog (Eli Lilly).
3. Now think about it. Would you rather have a rapid acting insulin available instead of syringes and pens to inject the insulin into yourself?
How about the simplicity?
How about not having to carry around needles, pens, swabs and alcohol?
Do you REALLY think analysts know more than diabetics about diabetes and insulin?
How about knowing you can bring your sugar down to safe levels much faster? The fear.
I don't think so.
This company is going to take at least 50 percent of that $6 billion market.
Multiply that by the standard price:sales ratio to get your MNKD stock value.